New Drug Doubles Survival Time in Advanced Pancreatic Cancer

Pancreatic cancer has one of the grimmest outlooks in oncology, so results presented at the 2026 meeting of the American Society of Clinical Oncology (ASCO) drew particular attention: a new daily pill roughly doubled how long patients with advanced disease survived. In an international phase 3 trial known as RASolute 302, involving around 500 people, the drug daraxonrasib extended median survival from 6.7 months to 13.2 months in patients whose cancer had progressed after previous treatment.

What makes the finding remarkable is the target. The drug is a RAS inhibitor, aimed at faulty versions of the KRAS gene that drive the majority of pancreatic cancers. For decades that gene was thought to be beyond the reach of medicine. “KRAS used to be considered undruggable, like nothing could touch it,” said Dr Sam Godfrey of Cancer Research UK, underscoring how a once-impossible goal has become a real, working treatment.

ASCO 2026 brought other advances too. In head and neck cancer, an injection called amivantamab was tested in the OrigAMI-4 study run by the Institute of Cancer Research in London. Among 102 patients with advanced disease, 43 saw their tumors shrink or disappear — about 42% — and in 15% of patients no detectable signs of cancer remained. “These results suggest this targeted treatment has the potential to offer a new option for some people,” said Dr Sarah Halford of the Cancer Research UK Centre for Drug Development.

Doubling survival in advanced pancreatic cancer does not amount to a cure, and both treatments still need further study and regulatory review before reaching most patients. But for diseases where progress has been agonizingly slow, extra months of life — and the cracking open of targets once written off as untouchable — represent exactly the kind of steady, hard-won advance that gradually turns fearsome diagnoses into manageable ones.